New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 17, 2014
16:27 EDTPRANPrana updates Alzheimer disease development program
Prana Biotechnology has provided an update on its clinical development program for Alzheimer's disease. In Professor Colin Masters' July presentation, which includes data from Prana's phase 2 IMAGINE and EURO trials, he noted that the starting amyloid burden level in the PBT2 treated participant group had an important bearing on the decrease of amyloid over time in that participant, whereas there was no such correlation in the placebo group. Separately, Prana has confirmed the top line finding that there is a very promising trend towards the preservation of brain volume in PBT2 treated patients compared to placebo patients.
News For PRAN From The Last 14 Days
Check below for free stories on PRAN the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 5, 2014
16:25 EDTPRANOn The Fly: Closing Wrap
Subscribe for More Information
10:28 EDTPRANHigh option volume stocks
Subscribe for More Information
September 4, 2014
18:50 EDTPRANPrana up 9.8% in after hours trading after receiving FDA orphan designation
Subscribe for More Information
18:06 EDTPRANPrana granted orphan status for treatment of Huntington disease
The FDA posted on its website that Prana Biotechnology has been granted orphan status for its treatment of Huntington's disease. Reference Link

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use